Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2020-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于2020年半年度募集资金实际存放与使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a special report on the actual deposit and use of raised funds for the half-year period of 2020. It details the fundraising activities, usage, management, and changes in investment projects related to the raised capital. It includes financial figures, approvals from the China Securities Regulatory Commission, and detailed tables on the use and balance of funds. The document is comprehensive and contains substantive financial data and analysis for a half-year period, specifically focusing on the use of raised funds. This matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes detailed financial information and analysis. It is not merely an announcement or certification, but a full report on fundraising usage and status for the half-year period ending June 30, 2020. H1 2020
2020-08-27 Chinese
独立董事关于第四届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is titled as "Independent Directors' Opinions" related to the 15th meeting of the 4th Board of Directors of the company. It contains independent directors' opinions on various matters such as related party transactions, use of raised funds, appointment of senior management, and guarantees for subsidiaries. The content is focused on governance and compliance with laws and regulations, rather than financial results or audit findings. It is not a full annual or interim report, nor an audit report. It is not a voting result or a remuneration report. The document is a formal statement from independent directors on board meeting matters, which fits best under Board/Management Information (MANG). The document length is short (1634 characters), but it contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2020-08-27 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2020 年半年度报告摘要' which translates to '2020 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and changes in assets and equity. It also discusses operational performance, business environment impacts (such as COVID-19), acquisitions, and changes in accounting policies. The length is over 6,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new vice general manager (副总经理) at 福安药业（集团）股份有限公司. It details the individual's background, qualifications, and confirms compliance with regulatory requirements. There is no financial data, no mention of financial results, no voting results, no legal proceedings, or other report types. The document is clearly about a management change announcement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a full report or other filing type.
2020-08-27 Chinese
第四届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 4th Supervisory Board of the company 福安药业（集团）股份有限公司. It includes the approval of the 2020 semi-annual report and its summary, a special report on the use of raised funds, and approval for guarantees for bank financing for a subsidiary. The document is short (1085 characters) and primarily serves as an announcement of meeting resolutions rather than the full semi-annual report itself. It does not contain detailed financial statements or substantive financial data but rather the supervisory board's approval and opinions on these reports and matters. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals, not the report itself or a detailed financial report.
2020-08-27 Chinese
关于股东减持计划实施进展情况的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding the progress of a shareholder's share reduction plan. It details the number of shares reduced, the methods of reduction (block trades and centralized bidding), dates, prices, and compliance with relevant securities laws and regulations. It does not contain financial statements, earnings data, or management discussion of financial results. It is specifically about the progress of a shareholding reduction plan by a significant shareholder (employee stock ownership plan). This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or shareholding structure changes. The document length is short (1543 characters), and it is not an announcement of a report publication but a substantive update on shareholding changes. Therefore, the correct classification is MRQ with high confidence.
2020-08-07 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.